27 February 2026

Two oral GLP-1 RAs go head-to-head

6 minute read

Simpler dosing and stronger efficacy may expand oral options for type 2 diabetes and obesity, pending regulatory approval.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...